Psyence Biomedical Stock Surges on White House Psychedelic Research Push
Psyence Biomedical's stock rose sharply following a White House executive order aimed at fast-tracking research into psychedelic therapies like ibogaine, though the company's lead drug remains in mid-stage trials.
Regulation
